X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (170) 170
Publication (24) 24
Book Chapter (3) 3
Newspaper Article (3) 3
Dissertation (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
index medicus (47) 47
oncology (46) 46
male (38) 38
female (37) 37
middle aged (35) 35
aged (33) 33
lung neoplasms - drug therapy (29) 29
adult (23) 23
cancer (23) 23
carcinoma, non-small-cell lung - drug therapy (23) 23
chemotherapy (23) 23
lung neoplasms - pathology (17) 17
article (15) 15
lung cancer (15) 15
aged, 80 and over (12) 12
animals (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
immunotherapy (12) 12
antineoplastic agents - therapeutic use (11) 11
lung cancer, non-small cell (11) 11
lung neoplasms - genetics (11) 11
treatment outcome (11) 11
carcinoma, non-small-cell lung - pathology (10) 10
care and treatment (10) 10
neoplasm staging (10) 10
open-label (10) 10
patients (10) 10
tumors (10) 10
carcinoma, non-small-cell lung - genetics (9) 9
mutations (9) 9
respiratory system (9) 9
solid tumors (9) 9
carcinoma (8) 8
mutation (8) 8
pembrolizumab (8) 8
pyrazoles - therapeutic use (8) 8
pyridines - therapeutic use (8) 8
research (8) 8
safety (8) 8
therapy (8) 8
biomarkers (7) 7
disease-free survival (7) 7
drug therapy (7) 7
hematology, oncology and palliative medicine (7) 7
metastasis (7) 7
prognosis (7) 7
abridged index medicus (6) 6
antineoplastic agents - adverse effects (6) 6
apoptosis (6) 6
cancer therapies (6) 6
combination (6) 6
fatigue (6) 6
inhibitor (6) 6
mice (6) 6
neoplasms - drug therapy (6) 6
protein kinase inhibitors - therapeutic use (6) 6
trial (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
carbazoles - therapeutic use (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
cell lung-cancer (5) 5
crizotinib (5) 5
docetaxel (5) 5
kaplan-meier estimate (5) 5
lung neoplasms - mortality (5) 5
lymphocytes (5) 5
metastases (5) 5
molecular targeted therapy (5) 5
piperidines - therapeutic use (5) 5
radiotherapy (5) 5
receptor protein-tyrosine kinases - genetics (5) 5
resistance (5) 5
small cell lung carcinoma - drug therapy (5) 5
alectinib (4) 4
analysis (4) 4
anaplastic lymphoma kinase (4) 4
antibodies (4) 4
antibodies, monoclonal - therapeutic use (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
antibodies, monoclonal, humanized - therapeutic use (4) 4
bevacizumab (4) 4
brain neoplasms - secondary (4) 4
carboplatin - administration & dosage (4) 4
carcinoma, non-small-cell lung - secondary (4) 4
diagnosis (4) 4
disease (4) 4
dose-response relationship, drug (4) 4
drug resistance, neoplasm (4) 4
egfr (4) 4
enzymes (4) 4
expression (4) 4
follow-up studies (4) 4
gefitinib (4) 4
genetic aspects (4) 4
immunohistochemistry (4) 4
lung cancer, small cell (4) 4
lung neoplasms - immunology (4) 4
lung neoplasms - metabolism (4) 4
lung neoplasms - therapy (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1497 - 1508
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1119 - 1128
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
ALK | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | 2ND-LINE TREATMENT | PHASE-II | IDENTIFICATION | TUMORS | ACTIVATING MUTATIONS | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Lymphomas | Pharmaceutical industry | Lung cancer | Tumors
Journal Article